BNP Paribas Financial Markets
APGE icon

BNP Paribas Financial Markets’s Apogee Therapeutics APGE Stock Holding History

BNP Paribas Financial Markets’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Sell
210,212
-9,887
-4% -$891K 0.01% 1068
2026
Q1 		$18.5M Buy
220,099
+210,134
+2,109% +$15.3M 0.01% 1210
2025
Q4 		$752K Sell
9,965
-28,258
-74% -$1.78M ﹤0.01% 3307
2025
Q3 		$1.52M Buy
38,223
+34,574
+947% +$1.32M ﹤0.01% 2825
2025
Q2 		$158K Buy
3,649
+941
+35% +$35.8K ﹤0.01% 3859
2025
Q1 		$101K Sell
2,708
-2,116
-44% -$81.8K ﹤0.01% 4036
2024
Q4 		$219K Buy
+4,824
New +$246K ﹤0.01% 3811

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets's APGE Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Apogee Therapeutics (APGE) stake by 4.5% in Q2 2026, selling an estimated $891K and leaving 210,212 shares worth $27.9M. The position accounts for 0.01% of the portfolio, ranked #1068.

BNP Paribas Financial Markets first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. 258 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • BNP Paribas Financial Markets held 210,212 shares of Apogee Therapeutics worth $27.9M as of Q2 2026.
  • BNP Paribas Financial Markets sold 9,887 Apogee Therapeutics shares in Q2 2026, an estimated $891K.
  • Apogee Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1068 holding.
  • BNP Paribas Financial Markets first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 258 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.